|Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104|
AV Patterson, DM Ferry, SJ Edmunds, Y Gu, RS Singleton, K Patel, ...
Clinical Cancer Research 13 (13), 3922-3932, 2007
|Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration|
SWS Yapa, J Li, K Patel, JW Wilson, MJ Dooley, J George, D Clark, ...
Antimicrobial agents and chemotherapy 58 (5), 2570-2579, 2014
|Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?|
AA Udy, J Lipman, P Jarrett, K Klein, SC Wallis, K Patel, CMJ Kirkpatrick, ...
Critical Care 19 (1), 28, 2015
|Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine|
KO Hicks, H Myint, AV Patterson, FB Pruijn, BG Siim, K Patel, WR Wilson
International Journal of Radiation Oncology* Biology* Physics 69 (2), 560-571, 2007
|The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104|
A Foehrenbacher, K Patel, M Abbattista, CP Guise, TW Secomb, ...
Frontiers in oncology 3, 263, 2013
|Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections|
SWS Yapa, J Li, CJH Porter, RL Nation, K Patel, MP McIntosh
Antimicrobial agents and chemotherapy 57 (10), 5087-5095, 2013
|Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for …|
K Patel, JA Roberts, J Lipman, SE Tett, ME Deldot, CM Kirkpatrick
Antimicrobial agents and chemotherapy 55 (12), 5868-5873, 2011
|Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters|
FB Pruijn, K Patel, MP Hay, WR Wilson, KO Hicks
Australian journal of chemistry 61 (9), 687-693, 2008
|A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture|
E Chigutsa, K Patel, P Denti, M Visser, G Maartens, CMJ Kirkpatrick, ...
Antimicrobial agents and chemotherapy 57 (2), 789-795, 2013
|Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice|
Y Gu, CP Guise, K Patel, MR Abbattista, J Lie, X Sun, GJ Atwell, M Boyd, ...
Cancer chemotherapy and pharmacology 67 (3), 543-555, 2011
|Analysis of the hypoxia-activated dinitrobenzamide mustard phosphate pre-prodrug PR-104 and its alcohol metabolite PR-104A in plasma and tissues by liquid chromatography–mass …|
K Patel, D Lewiston, Y Gu, KO Hicks, WR Wilson
Journal of Chromatography B 856 (1-2), 302-311, 2007
|A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity|
K Patel, SSF Choy, KO Hicks, TJ Melink, NHG Holford, WR Wilson
Cancer chemotherapy and pharmacology 67 (5), 1145-1155, 2011
|Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria|
K Patel, KT Batty, BR Moore, PL Gibbons, JB Bulitta, CM Kirkpatrick
Antimicrobial agents and chemotherapy 57 (1), 508-516, 2013
|PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma|
GK Abou-Alfa, SL Chan, CC Lin, EG Chiorean, RF Holcombe, ...
Cancer chemotherapy and pharmacology 68 (2), 539-545, 2011
|Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep|
K Patel, MT Rademaker, CMJ Kirkpatrick, CJ Charles, S Fisher, ...
British journal of pharmacology 166 (6), 1916-1925, 2012
|Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges|
K Patel, JA Simpson, KT Batty, S Zaloumis, CM Kirkpatrick
British journal of clinical pharmacology 79 (1), 97-107, 2015
|Pharmacokinetic concepts revisited-basic and applied|
K Patel, C MJ Kirkpatrick
Current pharmaceutical biotechnology 12 (12), 1983-1990, 2011
|Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model|
K Patel, KT Batty, BR Moore, PL Gibbons, CM Kirkpatrick
Journal of Antimicrobial Chemotherapy 69 (8), 2155-2163, 2014
|Pharmacokinetics and safety of oseltamivir in patients with end‐stage renal disease treated with automated peritoneal dialysis|
K Patel, CR Rayner, M Giraudon, MA Kamal, PN Morcos, R Robson, ...
British journal of clinical pharmacology 79 (4), 624-635, 2015
|Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia|
TN Doan, DCM Kong, K Patel, P Walker, A Spencer, CMJ Kirkpatrick
International journal of antimicrobial agents 44 (5), 450-457, 2014